

**Z-28020/500/2015-DC**  
**Directorate General of Health Services**  
**Office of DCG (I)**  
**(RTI CELL)**

FDA Bhawan, Kotla  
Road, New Delhi

Date: 27/10/2015

To,

Sh.Prashant Reddy T (Advocate),  
C/o Lex One Partners,  
E-19, LGF, Jungpura Extension,  
NewDelhi: 10 014

**Sub: Information under RTI Act, 2005 - Reg.**

Sir,

Please refer to you RTI letter no. NIL dated 06.04.2015 received in this office on dated 24.08.2015 regarding information under RTI Act, 2005.

The Point wise Reply as below:

**Reply to Point No. 1 (a):**

Copy of requested letter is attached.

**Reply to Point No. 1 (b) to (c) <sup>&</sup> Point 2:**

The information sought by the applicant regarding question no. 1(a), (b) and (c) has been considered to be exempted for disclosure under section 8(1) (h) of RTI Act being providing of such information would impede the process of investigation carried out by various CDSCO Zonal offices and State Licensing Authorities (SLAs). Further, there information also considered to be trade secret/commercial confidential nature and exempt for disclosure under section 8(1) d of RTI Act.

Yours Faithfully,

  
(Jayant Kumar)

Central Public Information Officer

Address of first appellate authority is as below:

The Drugs Controller General (India)  
FDA Bhawan, Opp. Mata Sundri College,  
Kotla Road, New Delhi – 110002

Secretary(Health & Family Welfare) from Consul General

This is further to the message sent by Cd'A a.i. Embassy of India, Hanoi on December 2013 regarding blacklisting of Indian pharmaceutical companies in Vietnam.

2. Enclosed herewith is a list of 66 foreign companies, whose products have been blacklisted for quality violations by the Drug Administration of Vietnam (DAV), during the period between January 1, 2011 to 25 October 2013. The list, which has been put on DAV website, includes 46 Indian companies.

3. In view of the fact that a large number of Indian companies have been listed defaulters by the Vietnamese authorities, it is requested that necessary background check on these companies may kindly be undertaken in India to see if there are complaints against them from other countries and steps be initiated to penalise them for bringing bad name to the Indian pharma industries abroad.

4. We would request that Mission/Post may kindly be kept apprised of the action taken so as to reassure the local authorities of our commitment to continue to be a reliable supplier to quality drugs/medicines.

[https://mail.gov.in/iwc\\_static/layout/shell.html?lang=en&2-7.01\\_091339](https://mail.gov.in/iwc_static/layout/shell.html?lang=en&2-7.01_091339)

26-12-2013